BIOADAPTIVES, INC. Annual Report - How They Did This Year

I’ve finished reviewing the latest update from BioAdaptives, Inc. If you are looking at this company, understand that this is not a typical business report. Here is the breakdown of what is happening behind the scenes.

1. What does this company do?

BioAdaptives researches and develops natural, plant-based supplements. They focus on products for brain health, weight management, and immune support. Their main projects include MyndMed for brain health and Zeranovia for weight loss. The company has spent over a decade on research and development and is currently preparing for a market launch in 2025.

2. Financial performance: The "Reality Check"

To put it bluntly: the company is not making a profit. For the year ending December 31, 2025, the company reported $0 in total revenue. Operating expenses—mostly professional fees, administrative costs, and research—led to a loss of about $450,000.

Because they have no cash coming in from sales, they rely entirely on selling stock or issuing shares to consultants and management to pay their bills. They spend about $35,000 to $40,000 per month. They have never paid dividends and plan to keep all future earnings to fund growth. This means the only way to see a return is if the stock price rises.

3. Major changes and leadership

There has been a lot of movement recently:

• Leadership: James E. Kneer is the CEO. To preserve cash, the company pays leaders with stock instead of salaries. This practice issues more shares, which reduces your ownership percentage in the company.
• Stock Moves: The company performed a 1-for-300 reverse stock split. This combined shares to keep the stock price from falling below a penny, which helps them maintain compliance with certain regulatory requirements.
• Share Dilution: The company has a massive pool of authorized shares. They frequently issue new shares to pay for legal, accounting, and consulting services. This constantly shrinks the percentage of the company owned by retail investors.

4. Key risks: What could go wrong?

This is a high-risk situation. Be aware of these hurdles:

• The "Going Concern" Warning: Auditors warned that the company’s debts exceed its assets. Without a major cash injection or sales revenue, the company faces significant challenges in maintaining operations.
• "Penny Stock" Status: The stock trades on the OTC Pink Sheets for about $0.013. It is highly volatile and can be difficult to sell quickly without impacting the share price.
• Limited Protection: Because they are not on a major exchange, they face fewer regulatory requirements. They lack independent committees to oversee executive pay, which creates potential conflicts of interest.
• Preferred Stock Power: The Board can issue "blank check" preferred stock. These shares often receive priority over common stock if the company is sold or liquidated, which puts retail investors at the back of the line.

5. Future outlook

The company is in a "make or break" phase. They must successfully launch their products to finally generate revenue after 12 years of development. Success depends on their ability to find distributors in a very competitive industry.

The Bottom Line: This is a tiny startup that has yet to prove it can sell products profitably. You are betting on a total turnaround. Given the lack of revenue and the constant issuance of new shares, this is a highly speculative play with a high risk of losing your entire investment. Before buying, ask yourself if you are comfortable with the fact that your ownership stake is likely to be diluted further as the company tries to fund its operations.